EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management

María Teresa Basurte-Elorz iD, Gemma Lacuey-Lecumberri, Nerea Mora-Ayestarán

European Cardiology Review · 02.11.2026

DOI: 10.15420/ecr.2026.01 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 02.11.2026. Verfasst von María Teresa Basurte-Elorz und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Hospital Universitario de Navarra Pamplona, Navarra, Spain. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive infiltrative cardiomyopathy increasingly recognised as a cause of heart failure. Advances in the understanding of its pathophysiology have enabled the development of targeted therapies, making ATTR-CM a paradigm of precision medicine in cardiology. Currently approved disease-modifying therapies, including two stabilisers (tafamidis and acoramidis) and one gene-silencing agent (vutrisiran), slow disease progression and reduce hospitalisations and mortality, particularly when initiated early. Because these therapies do not reverse established amyloid deposition, supportive management remains a critical component of care and presents distinct challenges. These include universal anticoagulation in AF, careful diuretic management, the benefits of sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists, and limited tolerance to other foundational heart failure therapies. On-going intensive research is expanding the therapeutic landscape, with several Phase III trials evaluating next-generation silencers, gene-editing strategies and amyloid-removal therapies. While these advances hold promise for disease reversal and prevention, important unresolved issues arise, including optimal treatment selection, monitoring strategies and economic sustainability.

Schlagwörter

Stichwörter der Autor:innen

Cardiac amyloidosisdisease-modifying treatmentsheart failuretargeted therapytransthyretintransthyretin amyloid cardiomyopathy

Autor:innen und Institutionen

  • Department of Cardiology, Hospital Universitario de Navarra Pamplona, Navarra, Spain.
  • Instituto de Investigación Sanitaria de Navarra (IdiSNA) Pamplona, Navarra, Spain.

ORCID-Profile: María Teresa Basurte-Elorz

Zitieren

APA

Basurte-Elorz, M. T., Lacuey-Lecumberri, G., & Mora-Ayestarán, N. (2026). Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management. European Cardiology Review. https://doi.org/10.15420/ecr.2026.01

Vancouver

Basurte-Elorz MT, Lacuey-Lecumberri G, Mora-Ayestarán N. Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management. European Cardiology Review. 2026. doi:10.15420/ecr.2026.01

BibTeX
@article{BasurteElorz2026,
  author = {Basurte-Elorz, María Teresa and Lacuey-Lecumberri, Gemma and Mora-Ayestarán, Nerea},
  title = {Transthyretin Amyloid Cardiomyopathy: Contemporary Pharmacological Management},
  journal = {European Cardiology Review},
  year = {2026},
  doi = {10.15420/ecr.2026.01}
}
Kostenlos starten →